Hard on the heels of good news for life sciences from the Spending Review and £50 million from the Technology Strategy Board for stratified medicine, two new initiatives have been launched by Universities and Science Minister David Willetts.
26 October, 2010
Last week, pharmaceutical heads met as a result of a drug recall after a mix up of breast cancer pills. The mishap raises the question: ‘Is there enough regulation to protect patients?’
21 October, 2010
Scientists have reported an important breakthrough in the control of oral anticoagulation, the blood thinning treatment currently given to approximately one million patients in the UK for thrombotic disorders.
20 October, 2010
Rexahn Pharmaceuticals have announced the publication of new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal of Medicinal Chemistry.
19 October, 2010
With access, cost and quality concerns plaguing pharmaceutical delivery systems both in the US as well as globally, the Next Generation Pharmaceutical Drug Discovery committee has been formed to confront, assess and deliver new strategies to secure the future of the industry. Meeting in Miami, Florida, the committee will discuss the state-of-play for personalized medicine, R&D challenges, translational medicine, imaging techniques and novel biomarkers – all connected by the pulse of the sector: the call for open innovation.
08 October, 2010
The frontline malaria treatment artemisinin could soon be treating more people for less cost, thanks to a research collaboration between Bradford and Shanghai.
06 October, 2010
Biomarker research and implementation is a hot topic for the pharmaceutical industry. While the positive potential of incorporating biomarker work during development is evident, the field has not reached its full potential.
01 October, 2010
Today, David Rutley, MP for Macclesfield, will officially open Cyprotex’s new toxicology facility – branded as Cyprotox® – at its headquarters in Macclesfield, UK.
01 October, 2010